Skip to main content
SpringerLink
Log in

Pharmacoepidemiology and Pharmacovigilance for Safety and Efficacy in Older People

  • Chapter
  • First Online:
Developing Drug Products in an Aging Society

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 26))

  • 1417 Accesses

Abstract

At the time of drug product approval, there is limited data on drug safety and efficacy in older patients. In old age there is an increased prevalence of chronic disease and of medication utilization resulting in multimorbidity and polypharmacy. While older people have potential for significant benefit from medicines, they are also susceptible to adverse drug events . Pharmacoepidemiology and pharmacovigilance studies provide real-world evidence on drug utilization and safety, and limited information on efficacy and effectiveness of drugs in older people. The reliability and validity of pharmacoepidemiologic studies have improved with advances in and standardization of study design and reporting, as well as development of objective measures to capture key aspects of geriatric medicine. Pharmacoepidemiologic studies now inform both clinical practice and medicines policy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hilmer SN, Gnjidic D, Abernethy DR. Pharmacoepidemiology in the post marketing assessment of the safety and efficacy of drugs in older adults. J Gerontol Ser A, Biol Sci Med Sci. 2012;67:181–8.

    Article  Google Scholar 

  2. Strom BL, Kimmel SE, Hennessy S, editors. Pharmacoepidemiology. 5th ed. Wiley-Blackwell; 2012.

    Google Scholar 

  3. Leinonen A, Koponen M, Hartikainen S. Systematic review: representativeness of participants in RCTs of acetylcholinesterase inhibitors. PLoS ONE. 2015;10:e0124500.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol: Off J Am Soc Clin Oncol. 2003;21:1383–9.

    Article  Google Scholar 

  5. Kitzman DW, Rich MW. Age disparities in heart failure research. JAMA. 2010;304:1950–1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bowling A, Dieppe P. What is successful ageing and who should define it? BMJ. 2005;331:1548–51.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Rowe JW, Kahn RL. Successful aging. Aging (Milano). 1998;10:142–4.

    CAS  Google Scholar 

  8. Havighust RJ. Successful Aging. In: Williams RH, Tibbits C, Donohue W, editors. Processes of aging. New York: Atherton Press; 1963. p. 299–320.

    Google Scholar 

  9. Peron EP, Gray SL, Hanlon JT. Medication use and functional status decline in older adults: a narrative review. Am J Geriatr Pharmacother. 2011;9:378–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Mahmoudi E, Jensen GA. Has medicare part D reduced racial/ethnic disparities in prescription drug use and spending? Health Serv Res. 2014;49:502–25.

    Article  PubMed  Google Scholar 

  11. Vitry AI, Roughead EE, Preiss AK, Ryan P, Ramsay EN, Gilbert AL, et al. Influence of comorbidities on therapeutic progression of diabetes treatment in Australian veterans: a cohort study. PLoS ONE. 2010;5:e14024.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Gnjidic D, Bennett A, Le Couteur DG, Blyth FM, Cumming RG, Waite L, et al. Ischemic heart disease, prescription of optimal medical therapy and geriatric syndromes in community-dwelling older men: a population-based study. Int J Cardiol. 2015;192:49–55.

    Article  PubMed  Google Scholar 

  13. Lemstra M, Blackburn D, Crawley A, Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28:574–80.

    Article  PubMed  Google Scholar 

  14. Pottegard A, Poulsen BK, Larsen MD, Hallas J. Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study. J Thromb Haemost. 2014;12:1413–8.

    Article  CAS  PubMed  Google Scholar 

  15. Sidman E, Probst LA, Darko W, Miller CD. Evaluation of dabigatran utilization and risk among hospitalized patients. Ann Pharmacother. 2014;48:349–53.

    Article  CAS  PubMed  Google Scholar 

  16. Gnjidic D, Le Couteur DG, Hilmer SN. Discontinuing drug treatments. BMJ. 2014;349:g7013.

    Article  PubMed  Google Scholar 

  17. Stavrou EP, Buckley N, Olivier J, Pearson SA. Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage. BMJ Open 2. 21 May 2012;2(3): e000880.

    Google Scholar 

  18. Hubbard RE, Peel NM, Scott IA, Martin JH, Smith A, Pillans PI, et al. Polypharmacy among inpatients aged 70 years or older in Australia. Med J Aust. 2015;202:373–7.

    Article  PubMed  Google Scholar 

  19. Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish prescribed drug register. Drug Saf. 2007;30:911–8.

    Article  PubMed  Google Scholar 

  20. Gill SS, Mamdani M, Naglie G, Streiner DL, Bronskill SE, Kopp A, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165:808–13.

    Article  PubMed  Google Scholar 

  21. Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167:781–7.

    Article  PubMed  Google Scholar 

  22. Salahudeen MS, Hilmer SN, Nishtala PS. Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. J Am Geriatr Soc. 2015;63:85–90.

    Article  PubMed  Google Scholar 

  23. Moriarty F, Bennett K, Fahey T, Kenny RA, Cahir C. Longitudinal prevalence of potentially inappropriate medicines and potential prescribing omissions in a cohort of community-dwelling older people. Eur J Clin Pharmacol. 2015;71:473–82.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ. 2004;329:44–7.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Vitry AI, Roughead EE, Ramsay EN, Preiss AK, Ryan P, Gilbert AL, et al. Major bleeding risk associated with warfarin and co-medications in the elderly population. Pharmacoepidemiol Drug Saf. 2011;20:1057–63.

    Article  PubMed  Google Scholar 

  26. Loboz KK, Shenfield GM. Drug combinations and impaired renal function—the ‘triple whammy’. Br J Clin Pharmacol. 2005;59:239–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. The cochrane database of systematic reviews 4: MR000034. 2014.

    Google Scholar 

  29. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624–32.

    Article  CAS  PubMed  Google Scholar 

  30. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45:419–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Hall GC, Sauer B, Bourke A, Brown JS, Reynolds MW, LoCasale R. Guidelines for good database selection and use in pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2012;21:1–10.

    Article  PubMed  Google Scholar 

  32. Pratt N, Roughead EE, Salter A, Ryan P. Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review. BMC Med Res Methodol. 2012;12:72.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Poole SG, Bell JS, Jokanovic N, Kirkpatrick CM, Dooley MJ. A systematic review of medication exposure assessment in prospective cohort studies of community dwelling older Australians. PLoS ONE. 2015;10:e0124247.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Gnjidic D, Hilmer SN. Use of potentially inappropriate medications in the care of frail older people. Aging Health. 2010;6:705–16.

    Article  Google Scholar 

  35. Kashyap M, Belleville S, Mulsant BH, Hilmer SN, Paquette A, le Tu M, et al. Methodological challenges in determining longitudinal associations between anticholinergic drug use and incident cognitive decline. J Am Geriatr Soc. 2014;62:336–41.

    Article  PubMed  Google Scholar 

  36. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49:M85–94.

    Article  CAS  PubMed  Google Scholar 

  37. Gnjidic D, Hilmer SN, Blyth F, Naganathan V, Cumming RG, Handelsman D, et al. High risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther. 2012;91:521–8.

    Article  CAS  PubMed  Google Scholar 

  38. Herr M, Robine JM, Pinot J, Arvieu JJ, Ankri J. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf. 2015;24:637–46.

    Article  PubMed  Google Scholar 

  39. Moulis F, Moulis G, Balardy L, Gerard S, Sourdet S, Rouge-Bugat ME, et al. Searching for a polypharmacy threshold associated with frailty. J Am Med Dir Assoc. 2015;16:259–61.

    Article  PubMed  Google Scholar 

  40. LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Newman AB, Kooperberg CL, et al. Statin use and incident frailty in women aged 65 years or older: prospective findings from the women’s health initiative observational study. J Gerontol Ser A Biol Sci Med Sci. 2008;63:369–75.

    Article  Google Scholar 

  41. Gray SL, LaCroix AZ, Aragaki AK, McDermott M, Cochrane BB, Kooperberg CL, et al. Angiotensin-converting enzyme inhibitor use and incident frailty in women aged 65 and older: prospective findings from the Women’s Health Initiative Observational Study. J Am Geriatr Soc. 2009;57:297–303.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854–64.

    Article  CAS  PubMed  Google Scholar 

  43. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15:291–303.

    Article  PubMed  Google Scholar 

  44. Heerdink ER, Leufkens HG, Koppedraaijer C, Bakker A. Information on drug use in the elderly: a comparison of pharmacy, general-practitioner and patient data. Pharm World Sci: PWS. 1995;17:20–4.

    Article  CAS  PubMed  Google Scholar 

  45. Gnjidic D, Le Couteur DG, Blyth FM, Travison T, Rogers K, Naganathan V, et al. Statin use and clinical outcomes in older men: a prospective population-based study. BMJ Open 3. 9 Mar 2013;3(3): e002333.

    Google Scholar 

  46. Rattinger GB, Burcu M, Dutcher SK, Chhabra PT, Rosenberg PB, Simoni-Wastila L, et al. Pharmacotherapeutic management of dementia across settings of care. J Am Geriatr Soc. 2013;61:723–33.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Hilmer SN, Gnjidic D. Rethinking psychotropics in nursing homes. Med J Aust. 2013;198:77.

    Article  PubMed  Google Scholar 

  48. Eaton CB, Lapane KL, Murphy JB, Hume AL. Effect of statin (HMG-Co-A-Reductase Inhibitor) use on 1-year mortality and hospitalization rates in older patients with cardiovascular disease living in nursing homes. J Am Geriatr Soc. 2002;50:1389–95.

    Article  PubMed  Google Scholar 

  49. Jacobs JM, Cohen A, Ein-Mor E, Stessman J. Cholesterol, statins, and longevity from age 70 to 90 years. J Am Med Dir Assoc. 2013;14:883–8.

    Article  PubMed  Google Scholar 

  50. Castillo C, Bulbena A, Serras E, Torrens M, Lopez-Colomes JL, Martinez MA, et al. Medical assessment in drug addicts: reliability and validity of the cumulative illness rating scale (substance abuse version). Eur Addict Res. 2004;10:112–7.

    Article  PubMed  Google Scholar 

  51. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale. Psychiatry Res. 1992;41:237–48.

    Article  CAS  PubMed  Google Scholar 

  52. Kim DH, Schneeweiss S. Measuring frailty using claims data for pharmacoepidemiologic studies of mortality in older adults: evidence and recommendations. Pharmacoepidemiol Drug Saf. 2014;23:891–901.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Cavallo P, Pagano S, Boccia G, De Caro F, De Santis M, Capunzo M. Network analysis of drug prescriptions. Pharmacoepidemiol Drug Saf. 2013;22:130–7.

    Article  PubMed  Google Scholar 

  54. Huybrechts KF, Rothman KJ, Brookhart MA, Silliman RA, Crystal S, Gerhard T, et al. Variation in antipsychotic treatment choice across US nursing homes. J Clin Psychopharmacol. 2012;32:11–7.

    Article  PubMed  Google Scholar 

  55. Daneman N, Gruneir A, Bronskill SE, Newman A, Fischer HD, Rochon PA, et al. Prolonged antibiotic treatment in long-term care: role of the prescriber. JAMA Intern Med. 2013;173:673–82.

    Article  CAS  PubMed  Google Scholar 

  56. Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994;272:781–6.

    Article  CAS  PubMed  Google Scholar 

  57. Zint K, Haefeli WE, Glynn RJ, Mogun H, Avorn J, Sturmer T. Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf. 2010;19:1248–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Gill SS, Seitz D, Rochon PA. Atypical antipsychotic drugs, dementia, and risk of death. JAMA. 2006; 295: 495–496; author reply 496–497.

    Google Scholar 

  59. Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170:96–103.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Moore AR, O’Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15:15–28.

    Article  CAS  PubMed  Google Scholar 

  61. American Geriatrics Society Expert Panel on Postoperative Delirium in Older A. American Geriatrics Society abstracted clinical practice guideline for postoperative delirium in older adults. J Am Geriatr Soc. 2015;63:142–50.

    Article  Google Scholar 

  62. Billioti de Gage S, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ. 2014;349:g5205.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401–7.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Hernandez I, Baik SH, Pinera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175:18–24.

    Article  PubMed  Google Scholar 

  65. Gnjidic D, Hilmer SN, Hartikainen S, Tolppanen AM, Taipale H, Koponen M, et al. Impact of high risk drug use on hospitalization and mortality in older people with and without Alzheimer’s disease: a national population cohort study. PLoS ONE. 2014;9:e83224.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Schneeweiss S, Patrick AR, Sturmer T, Brookhart MA, Avorn J, Maclure M, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007;45:S131–42.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. BMJ. 2014;349:g4517.

    Article  PubMed  Google Scholar 

  68. Lakey SL, Gray SL, Sales AE, Sullivan J, Hedrick SC. Psychotropic use in community residential care facilities: a prospective cohort study. Am J Geriatr Pharmacother. 2006;4:227–35.

    Article  PubMed  Google Scholar 

  69. Roughead EE, Kalisch Ellett LM, Ramsay EN, Pratt NL, Barratt JD, LeBlanc VT, et al. Bridging evidence-practice gaps: improving use of medicines in elderly Australian veterans. BMC Health Serv Res. 2013;13:514.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Weekes LM. A real-world, data-driven view of general practice prescribing. Med J Aust. 2014;201:504.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Royal North Shore Hospital, Kolling Institute of Medical Research and Sydney Medical School, University of Sydney, Kolling Building, St Leonards, Sydney, NSW, 2065, Australia

    Sarah N. Hilmer & Danijela Gnjidic

  2. Faculty of Pharmacy, University of Sydney, Sydney, NSW, Australia

    Danijela Gnjidic

Authors
  1. Sarah N. Hilmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Danijela Gnjidic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah N. Hilmer .

Editor information

Editors and Affiliations

  1. Graz University of Technology, Graz, Austria

    Sven Stegemann

Rights and permissions

Reprints and permissions

Copyright information

© 2016 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Hilmer, S.N., Gnjidic, D. (2016). Pharmacoepidemiology and Pharmacovigilance for Safety and Efficacy in Older People. In: Stegemann, S. (eds) Developing Drug Products in an Aging Society. AAPS Advances in the Pharmaceutical Sciences Series, vol 26. Springer, Cham. https://doi.org/10.1007/978-3-319-43099-7_12

Download citation

Publish with us

Policies and ethics

Search

Navigation